237 related articles for article (PubMed ID: 26604686)
1. The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors.
Campione E; Paternò EJ; Candi E; Falconi M; Costanza G; Diluvio L; Terrinoni A; Bianchi L; Orlandi A
Drug Des Devel Ther; 2015; 9():5843-50. PubMed ID: 26604686
[TBL] [Abstract][Full Text] [Related]
2. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.
Campione E; Diluvio L; Paternò EJ; Chimenti S
Am J Clin Dermatol; 2010; 11(1):45-50. PubMed ID: 20000874
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Müller-Decker K
Cancer Metastasis Rev; 2011 Dec; 30(3-4):343-61. PubMed ID: 22038018
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.
Ritland SR; Gendler SJ
Carcinogenesis; 1999 Jan; 20(1):51-8. PubMed ID: 9934849
[TBL] [Abstract][Full Text] [Related]
7. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention.
Earnest DL; Hixson LJ; Alberts DS
J Cell Biochem Suppl; 1992; 16I():156-66. PubMed ID: 1305681
[TBL] [Abstract][Full Text] [Related]
8. Is cyclooxygenase-2 important in skin carcinogenesis?
Fischer SM
J Environ Pathol Toxicol Oncol; 2002; 21(2):183-91. PubMed ID: 12086405
[TBL] [Abstract][Full Text] [Related]
9. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus.
Carlton PS; Gopalakrishnan R; Gupta A; Liston BW; Habib S; Morse MA; Stoner GD
Cancer Res; 2002 Aug; 62(15):4376-82. PubMed ID: 12154043
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment.
Krishnan AV; Feldman D
Endocr Relat Cancer; 2010 Mar; 17(1):R19-38. PubMed ID: 19926709
[TBL] [Abstract][Full Text] [Related]
12. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention.
Zhan H; Zheng H
Am J Clin Dermatol; 2007; 8(4):195-200. PubMed ID: 17645375
[TBL] [Abstract][Full Text] [Related]
13. Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines.
Yoshitake R; Saeki K; Watanabe M; Nakaoka N; Ong SM; Hanafusa M; Choisunirachon N; Fujita N; Nishimura R; Nakagawa T
Vet J; 2017 Mar; 221():38-47. PubMed ID: 28283079
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Wilgus TA; Koki AT; Zweifel BS; Kusewitt DF; Rubal PA; Oberyszyn TM
Mol Carcinog; 2003 Oct; 38(2):49-58. PubMed ID: 14502644
[TBL] [Abstract][Full Text] [Related]
16. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
Xu S; Rouzer CA; Marnett LJ
IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
18. Effect of piroxicam on matrix metalloproteinase 2 and apoptosis.
Mirshafiey A; Vaezzadeh F; Khorramizadeh MR; Saadat F
Int J Tissue React; 2004; 26(1-2):1-7. PubMed ID: 15573686
[TBL] [Abstract][Full Text] [Related]
19. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
20. COX-2: a target for prevention and treatment of esophageal cancer.
Altorki N
J Surg Res; 2004 Mar; 117(1):114-20. PubMed ID: 15013721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
